Who owns LB PHARMACEUTICALS INC (LBRX)? Elite investor 13F holders
2 tracked elite investors reported holding LB PHARMACEUTICALS INC as of 2026-06-30, including Caligan Partners, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression;…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | LB PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 46672562.00 USD | 1438070.000000 | Shares | hold | Original filing |
| D.E. Shaw | LB PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 438727.00 USD | 13518.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.